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lioblastoma multiforme (GBM) is the most
aggressive form of human glioma and
accounts for approximately 60% to 70% of
all malignant gliomas.1,2 Based on data from the 2013
Central Brain Tumor Registry of the United States
(CBTRUS) statistical report on primary brain and
CNS tumors in the United States, an estimated 9,600
to 11,200 new cases of GBM will be diagnosed in
2014.1,2 Virtually all patients with newly diagnosed
GBM relapse despite maximal multimodality treat-
ment,3 with a median time to recurrence of approx-
imately 7 months.4 The prognosis for patients with
recurrent GBM is even worse. The median
progression-free survival (PFS) was only 9 weeks in
the pre-bevacizumab era.5 In 2009, bevacizumab
received accelerated approval from the US Food
and Drug Administration (FDA) for the treatment
for recurrent GBM based on two single-arm studies
with favorable response rates and PFS data.1,6,7
Formal phase III data is not available in the recurrent
setting, however phase III comparison of bevacizu-
mab versus placebo in newly diagnosed glioblastoma
patients failed to demonstrate prolongation of sur-
vival with bevacizumab.1,8 A major challenge in
treatment of recurrent GBM, particularly with bev-
acizumab, is that the tumor eventually develops
resistance to the drug. Moreover, bevacizumab-
treated tumors may convert to a more aggressive
phenotype and exhibit infiltrative tumor growth as
observed on magnetic resonance imaging (MRI).9,10
Furthermore, patients with recurrent GBM who
progress following bevacizumab therapy are typi-
cally resistant to subsequent cytotoxic chemothera-
pies.1,11,12 Therefore, new treatments that can offer
a different mechanism of action and potentially
overcome treatment resistance are desperately
needed.
The NovoTTF-100A™ System (Novocure, Ltd.,
Haifa, Israel) is a novel antimitotic cancer therapy
approved in 2011 by the US FDA for the treatment of
recurrent supratentorial GBM,13,14 based on the
results of a phase III trial comparing NovoTTF
Therapy with best chemotherapy according to physi-
cian choice.15 The unique mechanism of action of
NovoTTF Therapy involves localized delivery of
alternating low-intensity, intermediate-frequency,tumor-treating fields (TTFields) via non-invasive
transducer arrays attached to the patient’s scalp.14
In preclinical studies, TTFields have been shown to
selectively kill or arrest the growth of rapidly divid-
ing cancer cells including glioblastoma cell lines by
disrupting both mitotic spindle formation and nor-
mal cytokinesis by interrupting cytoplasmic furrow
formation.16–20
The pivotal phase III (EF-11) trial that led to FDA
approval of the device compared NovoTTF Therapy
(n ¼ 120) with best chemotherapy according to
physician’s choice (n ¼ 117) in recurrent GBM
patients from 28 institutions in seven countries.15
More than 80% of patients in the study had failed
two or more prior chemotherapies, and 20% had
experienced recurrence while on bevacizumab.
Seventy-eight percent of the 116 patients who
started NovoTTF Therapy completed at least one
full-treatment course (4 weeks). The results demon-
strated comparable median OS with NovoTTF Ther-
apy compared with chemotherapy (6.6 v 6.0
months; hazard ratio [HR], 0.86; 95% confidence
interval [CI], 0.66 to 1.12; P ¼ .27), together with
fewer severe adverse events (6% v 16%, P ¼ .022)
and improved quality-of-life measures for the
NovoTTF Therapy arm compared with the chemo-
therapy arm. The most common adverse events with
NovoTTF Therapy were mild to moderate skin
irritation associated with the transducer arrays.
Systemic adverse events commonly associated with
chemotherapy were generally absent in patients
receiving NovoTTF Therapy.
Given the mechanism of action of TTFields and the
results of preclinical studies, optimal device compli-
ance is required for therapeutic effectiveness with
NovoTTF Therapy. NovoTTF Therapy does not have
a half-life, therefore it requires continuous application
to exert a therapeutic effect. This differs from systemic
chemotherapy, which exerts anticancer effects
between administrations due to the drug pharmacoki-
netics. Based on modeling of tumor growth kinetics
and supporting preclinical and clinical data, NovoTTF
Therapy must be administered almost “continuously”
for at least 4 weeks in order to halt tumor growth and
subsequently demonstrate an objective response.21,22
Recommended administration of NovoTTF Therapy
M.M. Mrugala et alS6isZ18 hours per day for each 4-week treatment
cycle.21 A post hoc analysis of the phase III trial data
recently showed significantly longer median OS in
NovoTTF Therapy patients with a maximal monthly
compliance rateZ75% (Z18 hours daily) versus those
with ao75% compliance rate (7.7 v 4.5 months,
P ¼ .042) (see Kanner et al in this supplement). A
recent responder analysis also demonstrated very high
compliance rates490% in EF-11 responders.23
The Patient Registry Dataset (PRiDe) is a registry
of 457 recurrent GBM patients who received
NovoTTF Therapy in the clinical practice setting
on the US commercial prescription-use program
between October 2011 and November 2013.
Patients treated in clinical trials often differ from
those who receive treatment in the real-world set-
ting due to patient selection criteria and frequently
represent a less homogenous group. Hence registry
data can be an important source of additional
information about the efficacy and safety of a newly
approved therapy. This report analyzes data from
PRiDe to help us better understand the potential
benefits of NovoTTF Therapy for patients with
recurrent GBM, including analyses of median OS,
tolerability, and the relationship between survival
and compliance as well as other prognostic factors.METHODS
Patients and Data Collection
PRiDe data were collected from all patientsZ18
years old with recurrent GBM who began commer-
cial treatment with NovoTTF Therapy in the United
States between October 2011 and November 2013.
All participating patients provided written informed
consent to use protected health information to
advance the understanding of NovoTTF Therapy.
Recurrent GBM was defined as histologically-
confirmed, supratentorial GBM (World Health
Organization grade IV astrocytoma) with radiologi-
cally confirmed evidence of disease progression, as
defined by the Macdonald criteria,24 following treat-
ment with radiotherapy with or without concom-
itant and/or adjuvant chemotherapy. Patients who
received NovoTTF Therapy were not restricted to
the number or types of prior therapies or recur-
rences. Information about combination use of
NovoTTF Therapy as part of the prescription-use
program was not captured. Therefore some patients
may have received combination therapy (chemo-
therapy or anti-vascular endothelial growth factor
[VEGF] agents) rather than monotherapy.
Baseline characteristics were assessed by manual
patient chart review. OS was collected using the
Social Security Death Date Registry and obituaries.
Novocure started collecting compliance data centrallyin January 2013, so such data are only available for
under two thirds of patients in the registry. A monthly
compliance assessment was performed for each
patient by computer download of an internal log file
which captures the cumulative amount of time
therapy is delivered to the patient. Patient compliance
was calculated as the average percentage of each day
the system was delivering fields (out of each 24-hour
period). In addition, other prognostic factors, such as
the number of prior recurrences, age, KPS, prior
bevacizumab use, and any debulking surgery were
captured and analyzed. Adverse events were recorded
prospectively according to National Cancer Institute
Common Toxicity Criteria. Quality-of-life measures
were not assessed in PRiDe.Statistical Analysis
The OS and treatment duration curves were
constructed using the Kaplan-Meier method. OS in
PRiDe was compared to OS for patients receiving
NovoTTF Therapy or best chemotherapy in the
phase III EF-11 trial (ITT population) using a log-
rank (Mantel-Cox) test. Patient or disease character-
istics prognostic for survival with NovoTTF Therapy
were assessed using a Cox proportional hazards
model (P value of .15 for significant interactions).
Subgroup analyses were performed on patient/clin-
ical characteristics found to be significantly corre-
lated with OS. A log-rank test was used to compare
the relationship between OS and daily compliance
(o75% vZ75%), prior debulking surgery (yes, no),
KPS (90–100, 70–80, 10–60), recurrence number
(1st, 2nd, 3rd–5th recurrence) and prior bevacizu-
mab use (prior use v naı¨ve).RESULTS
Patient Characteristics
Four-hundred fifty-seven patients with recurrent
GBM were treated with NovoTTF Therapy between
October 2011 and November 2013 at 91 oncology
centers. This population is more than three times the
120 subjects treated with NovoTTF monotherapy, as
well as the 117 subjects treated with chemotherapy,
in the phase III EF-11 trial, from which we were
making a comparison. Baseline patient character-
istics are presented in Table 1. Patient characteristics
(age and gender) were generally similar in PRiDe and
the two treatment groups in the EF-11 trial. Approx-
imately one third of patients treated commercially
with NovoTTF Therapy were women, which is an
important observation given the perceived cosmetic
considerations of head shaving and array placement.
Table 1. Baseline Patient Characteristics in PRiDe and EF-11 Trial
Characteristic
PRiDe NovoTTF
Therapy (n ¼ 457)
EF-11 NovoTTF
Therapy (n ¼ 120)
EF-11
Chemotherapy
(n ¼ 117)
Age (y) Median (range) 55 (18–86) 54 (24–80) 54 (29–74)
Gender Male 67.6% 77% 62%
Female 32.4% 23% 38%
KPS Median (range) 80 (10–100) 80 (50–100) 80 (50–100)
10–60 19.0% NA NA
70–80 46.6% NA NA
90–100 30.9% NA NA
Unknown 3.5% NA NA
Recurrence Median (range) 2 (1–5) 2 (1–5) 2 (1–4)
First 33.3% 9% 15%
Second 26.9% 48% 46%
Third to Fifth 27.4% 43% 39%
Unknown 12.5% 0% 0%
Prior treatments Bevacizumab 55.1% 19% 18%
RT þ temozolo-
mide
77.9% 86% 82%
Debulking surgery 63.9% 79% 85%
Carmustine wafers 3.7% NA NA
Abbreviations. KPS, Karnofsky performance status; NA, not available; RT, radiotherapy.
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No new adverse events were detected in PRiDe
compared to those found in EF-11. The most com-
mon device-related adverse events associated with
NovoTTF Therapy in the registry were skin reac-
tions/irritation and heat sensations on the scalp
beneath the transducer arrays (Table 2). Patients
sometimes described these events as “warmth” or
“tingling” sensations, none of which were associated
with injury to the patient. Systemic adverse events,
which were often associated with chemotherapy
(eg, gastrointestinal, hematologic, and infectious
adverse events), were rare for patients treated with
NovoTTF Therapy in the registry.
Survival Rates
Figure 1 presents Kaplan-Meier curves of OS for
patients treated with NovoTTF Therapy in the
clinical practice setting (PRiDe) and those who
received NovoTTF Therapy or best chemotherapy
as part of the EF-11 trial (ITT population; see Kanner
et al in current supplement). Median OS on
NovoTTF Therapy appeared to be markedly longer
in PRiDe than in the EF-11 trial (9.6 v 6.6 months).
Median OS was also significantly longer with
NovoTTF Therapy in PRiDe than with best chemo-
therapy group in the EF-11 trial (9.6 v 6.0 months).
One- and 2-year OS rates for NovoTTF Therapy
patients in PRiDe were more than double those seenwith either NovoTTF Therapy or best chemotherapy
in the EF-11 trial (Table 3).15,25
Median treatment duration for patients in PRiDe
was 4.1 months (95% CI, 3.5–4.8). In comparison,
the median treatment duration in the EF-11 study
was 2.3 months (95% CI, 2.1– 2.4) for NovoTTF
Therapy arm and 2.1 months (95% CI, 2.0–2.9) for
best chemotherapy. Figure 2 shows the fraction of
NovoTTF Therapy patients still on treatment over
time. Roughly 50% were still on NovoTTF Therapy
after 4 months from treatment start, and roughly 10%
were still on NovoTTF Therapy at 2 years after
treatment start.Compliance as a Prognostic Factor and Its
Relationship to OS
Because of the major difference in the OS in
patients registered in PRiDe as compared to the OS
of subjects treated with NovoTTF monotherapy in
EF-11, we sought to identify the prognostic factors in
the former cohort. The first prognostic factor we
analyzed was NovoTTF treatment compliance
because it was found to be prognostically important
in EF-11 in a post hoc analysis. Compliance data
were collected centrally starting in January 2013
and, therefore, were only available for 287 of the 457
patients (63%) in the registry. The median daily
compliance was 70% for patients treated with
NovoTTF Therapy in PRiDe (range, 12%–99%). One
Table 2. Adverse Events in Patients With
Recurrent Glioblastoma Multiforme Treated
With NovoTTF Therapy in PRiDe
Adverse event
Percentage of Patients
PRiDe (n ¼ 457)
Skin reaction 24.3
Heat sensation 11.3
Neurological disorder 10.4
Seizure 8.9
Electric sensation 7.7
Headache 5.7
Pain/discomfort 4.7
Fall 3.9
Psychiatric disorder 2.9
Gastrointestinal
disorder
2.9
Fatigue 2.5
Vascular disorder 1.6
Weakness 1.4
Infections 1.4
Eye disorder 1.3
M.M. Mrugala et alS8hundred twenty-seven (44%) achieved daily compli-
ance ofZ75% of each day, while 160 (56%) had
daily compliance ofo75%. As illustrated in Figure 3,
median OS was significantly longer in patients with a
NovoTTF Therapy daily complianceZ75% than in
those witho75% daily compliance (13.5% v 4.0%;
HR, 0.43; 95% CI, 0.29–0.63; Po.0001).Figure 1. Kaplan-Meier overall survival (OS) curves for
patients with recurrent glioblastoma multiforme treated
with NovoTTF Therapy in PRiDe or with NovoTTF Ther-
apy or best chemotherapy in the EF-11 trial (P ¼ .0003).Other Prognostic Factors
The Cox proportional hazards model identified
the presence or absence of debulking surgery,
number of prior recurrences, compliance, KPS, and
prior bevacizumab therapy as significant indepen-
dent predictors of OS in patients treated with
NovoTTF Therapy in PRiDe (Po.15). Table 4
presents log-rank OS testing between patient sub-
groups in PRiDe for each of these prognostic factors;
Figure 4 presents Kaplan-Meier survival curves for
these same factors. First, no difference in median OS
was observed between patients who did not have
surgical debulking and those who did (8.9 v 9.8,
respectively; HR, 1.1; 95% CI, 0.8–1.5; P ¼ .7927).
Second, recurrent GBM patients treated with
NovoTTF Therapy in clinical practice at their first
recurrence experienced a significantly longer
median OS as compared to patients treated at their
second, third, or subsequent recurrence (20 months
compared to 8.5 and 4.9 months, respectively; HR,
0.6; 95% CI, 0.4–0.9; P ¼ 0.0271 and HR, 0.3; 95%
CI, 0.2–0.5; Po.0001). It should be noted that a
greater percentage of patients in PRiDe were at their
first GBM recurrence compared with patients treated
with NovoTTF Therapy or best chemotherapy in the
EF-11 trial (33.3% v 9% and 15%, respectively). In
addition, differences were also apparent between
patients in PRiDe and those in the EF-11 trial with
respect to prior treatments. More than half of
NovoTTF Therapy patients in PRiDe had previously
received bevacizumab (55.1%), compared with only
19% of NovoTTF monotherapy and 18% of best
active chemotherapy cohorts in the EF-11 trial.
Third, recurrent GBM patients with KPSZ90 exhib-
ited a near doubling of median OS compared with
patients with a KPS of 70–80, median OS 14.8 versus
7.7 months, respectively, HR 0.6 (95% CI, 0.4–0.9), P
¼ .0070. Lastly, the survival of bevacizumab-naı¨ve
patients was significantly longer compared to
patients who had received prior bevacizumab before
starting NovoTTF Therapy, with a respective median
OS 13.4 versus 7.2 months, HR 0.5 (95% CI, 0.4–0.7),
Po.0001. These data suggest that, within thisTable 3. One- and 2-Year Overall Survival
Rates for Patients With Recurrent Glioblas-
toma Multiforme Treated With NovoTTF Ther-
apy in PRiDe and EF-11 Trial, and With Best
Chemotherapy in the EF-11 Trial
Endpoint
PRiDe
NovoTTF
Therapy
(n ¼ 457)
EF-11
NovoTTF
Therapy
(n ¼ 120)
EF-11
Chemo-
therapy
(n ¼ 117)
1-Year survival 44% 20% 20%
2-Year survival 30% 9% 7%
Figure 2. Fraction of NovoTTF Therapy patients alive by
treatment duration (PRiDe).
PRiDe registry for glioblastoma patients receiving NovoTTF-100A System S9heterogeneous group of patients registered in PRiDe,
there were subsets of patients who derived signifi-
cant benefit from NovoTTF Therapy.Figure 3. Overall survival (OS) by daily compliance with
NovoTTF Therapy for recurrent glioblastoma multiforme
patients in PRiDe.DISCUSSION
The Patient Registry Dataset, or PRiDe, represents
457 unselected patients with recurrent GBM who
received NovoTTF Therapy in a real-world, clinical
practice setting across 91 cancer centers in the
United States between October 2011 and November
2013. No new, unexpected adverse events were
detected with NovoTTF Therapy in this cohort.
Similar to the EF-11 trial,15 the most common
adverse events associated with NovoTTF Therapy
were mild to moderate skin reactions localized to the
scalp beneath the transducer arrays. These reactions
were easily treated with topical corticosteroids or
antibiotics, were not associated with serious injury
to the scalp, and typically did not require interrup-
tion of treatment. Some patients in PRiDe reported
subjective sensations beneath the transducer arrays,
often described as “warmth” or “tingling.” These heat
or electric sensations were captured as adverse
events in PRiDe (“skin reaction”), but not in the EF-
11 trial. These sensations occur when the contact
between transducer arrays and the skin is subopti-
mal, and usually indicate the presence of hair
regrowth. In these instances, re-shaving the head
can re-establish optimal contact between the skin
and transducer arrays. Furthermore, systemic
adverse events commonly observed with chemo-
therapy were largely absent in patients treated withNovoTTF Therapy in PRiDe as they were in the EF-11
trial.15
Patients receiving NovoTTF Therapy for recurrent
GBM demonstrated a median OS of 9.6 months in
clinical practice. This compares favorably to the
reported median OS for the EF-11 pivotal trial cohort
treated with NovoTTF monotherapy, where median
OS was 6.6 months, and to OS of patients who
received treatments for recurrent GBM in other
clinical trials.26–29 For example, recent reports of
median OS in recurrent GBM patients treated with
bevacizumab are in the range of 6 to 10.5
months,7,12,26–28,30 and those treated with temozo-
lomide in the range 6 to 9 months.31–33 It should be
noted that many of the longer term survival out-
comes noted in clinical trials of bevacizumab and
temozolomide in recurrent GBM included small
sample sizes and none were randomized.
The difference between the OS seen in clinical
practice and in the EF-11 trial may in part be due the
greater percentage of patients with a first GBM
recurrence in PRiDe versus patients in the EF-11
study (33.3% v 9%, respectively). This observation is
also supported by a prior post hoc analysis of EF-11
that showed a significantly longer median OS in
patients treated with NovoTTF Therapy at their first
or second recurrence compared to those treated at
third or subsequent recurrences. Furthermore, when
used as intended (daily complianceZ75% orZ18
hours daily), the median OS for patients treated with
NovoTTF Therapy in PRiDe was remarkably high at
13.5 months compared to only 4.0 months in those
who had suboptimal compliance (daily compliance
Table 4. Overall Survival (OS) in Patients With Recurrent Glioblastoma Multiforme Treated With
NovoTTF Therapy in PRiDe Based on Prognostic Factors Signiﬁcantly Correlated With OS in the Cox
Proportional Hazards
Variable Median OS (mo) Hazard Ratio P Value
No. of recurrences
1st 20 — —
2nd 8.5 0.6 (95% CI, 0.4–0.9) .0271a
3rd-5th 4.9 0.3 (95% CI, 0.2–0.5) o.0001b
Compliance
Z75% 13.5 0.4 (95% CI, 0.3–0.6) o.0001
o75% 4.0
Karnofsky performance status (KPS)
90–100 14.8 — —
70–90 7.7 0.6 (95% CI, 0.4–0.9) .0070c
10–60 6.1 0.4 (95% CI, 0.2–0.6) o.0001d
Bevacizumab use
Naïve 13.4 0.5 (95% CI, 0.4–0.7) o.0001
Prior use 7.2
Debulking surgery
No 8.9 1.1 (95% CI, 0.8–1.5) .7927
Yes (any surgery) 9.8
a First recurrence compared to 2nd recurrence.
b First recurrence compared to 3rd–5th recurrence.
c KPS 90–100 compared to KPS 70–80.
d KPS 90-100 compared to KPS 10–60.
M.M. Mrugala et alS10o75% oro18 hours daily). Kanner et al (see accom-
panying Kanner article in this supplement) recently
reported similar findings when re-examining data
from the EF-11 trial: median OS was significantly
longer with a monthly compliance rate for NovoTTF
TherapyZ75% thano75% (7.7 v 4.5 months, P ¼
.042). The compliance findings from each of these
studies are consistent with the mechanism of action
of NovoTTF Therapy, which depends on almost
continuous administration (Z18 hours per day) for
a prolonged period of time (Z4 weeks).21,22 How-
ever, patients in PRiDe who had suboptimal compli-
ance were also found to have lower KPS and were, in
general, at later stages of their disease. It is unclear
whether they also may have had larger tumors or
inadequate social support. Nevertheless, consistent
with previous findings, our data suggest that applying
NovoTTF Therapy to patients with higher perform-
ance status, earlier in their recurrence and ensuring
treatment compliance, can maximize clinical benefit.
Additional analyses uncovered other prognostic
factors that were important for patients in PRiDe. Of
interest, in our subgroup analysis, 55.1% of patients
in PRiDe who received prior bevacizumab therapy
demonstrated a shorter median OS of 7.2 months, as
compared to a median OS of 13.4 months in
bevacizumab-naı¨ve patients. The shorter survival
in patients treated previously with bevacizumab
may be a result of acquired tumor resistance and
development of a more aggressive phenotype withinfiltrative tumor progression on MRI.9,10 Moreover,
patients with recurrent GBM tumors that progress
while on bevacizumab therapy are typically resistant
or refractory to subsequent cytotoxic chemother-
apy,1,11,12 and have a median OS of just 2.7 months.
Therefore, the PRiDe data suggest that at least a
percentage of bevacizumab-resistant tumors remain
responsive to NovoTTF Therapy. Future analysis of
responders and nonresponders to NovoTTF Therapy
will need to include molecular genetic analysis of the
tumor (and especially MGMT methylation status),
the estimated tumor size (volume) as measured by
fluid attenuated inversion recovery sequence on
MRI, and more detailed analysis of the extent of
resection.
Our analysis of KPS in PRiDe also demonstrated
that higher KPS correlated with longer OS. It is
unclear at this time whether or not patients who
had KPS 90–100 had smaller tumors than the rest of
the cohort or perhaps more extensive resections.
KPS is often, but not always, a measure of tumor
size, particularly the microscopic invasive compo-
nent of the glioblastoma. Whether or not the
median tumor size, as measured by gadolinium-
enhanced T1-weighted and/or FLAIR MRI, differ
between the subgroup with KPS 90–100 versus
70–90 and 10–60 remains to be determined. Of
note, age was not a predictor of OS in the
PRiDe dataset when evaluated either by direct
correlation (Pearson correlation coefficient) or a
Figure 4. Kaplan-Meier overall survival (OS) curves for recurrent glioblastoma multiforme patients treated with NovoTTF
Therapy in PRiDe based on (A) recurrence number, (B) Karnofsky performance status (KPS), (C) prior bevacizumab use, and
(D) prior debulking surgery, respectively.
PRiDe registry for glioblastoma patients receiving NovoTTF-100A System S11Cox proportional hazards model (P ¼ .20). In
addition, age was not correlated with compliance
in the PRiDe (correlation coefficient ¼ 0.02; P ¼
.37). Taken in the context of the overall efficacy
results, these findings suggest NovoTTF Therapy
works well for patients of all ages and that advanced
age is not associated with lower compliance. It
would also be interesting to know if marital status
(or other measures of patient support) influence
compliance and survival, but data on marital status
were not collected in PRiDe.
Finally, the PRiDe dataset did not capture patients
on combination treatments in which additionalbiologic therapy or chemotherapy were added to
NovoTTF Therapy. It is possible that the longer
survival seen in clinical practice with NovoTTF
Therapy compared to NovoTTF monotherapy in
the EF-11 trial is a reflection of combination use of
NovoTTF Therapy with biological agents or cyto-
toxic chemotherapy. In fact, preclinical data have
suggested that TTFields are additive or even syner-
gistic with chemotherapies in cell culture.34–36
Therefore, the potential benefits of combining
NovoTTF Therapy with other systemic therapies
warrant further investigation. A phase III trial of
NovoTTF Therapy together with temozolomide
M.M. Mrugala et alS12compared to temozolomide alone is currently
ongoing in patients with newly diagnosed glioblas-
toma. The results of this trial will shed light on the
possible additive or synergistic effects of NovoTTF
Therapy and systemic chemotherapy.
In summary, PRiDe and the EF-11 trial represent
one of the largest datasets of patients with recurrent
GBM published to date, containing 700 patients in
total, 567 of whom were treated with NovoTTF
Therapy. The results, individually and collectively,
provide further support for the use of NovoTTF
Therapy to treat recurrent, supratentorial GBM.
Observations from the post-marketing registry dem-
onstrate that the safety and efficacy observed with
NovoTTF Therapy in a clinical trial extend to the
real-world, clinical practice setting. Future investiga-
tions may need to include NovoTTF Therapy in
combination with other recurrent GBM treatments,
which together may have additive or synergistic
effects on patient outcomes.Acknowledgments
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